Disease progression and the application of evidence-based treatment guidelines diagnose it early: A case for screening and appropriate management

Journal of Managed Care Pharmacy

Volumn 13, Issue 9 SUPPL. D, 2007, Pages

  Manley, Harold J ^a  

^a Clinical Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; NICOTINIC ACID; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; GLOMERULAR DYSFUNCTION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEALTH CARE PLANNING; HEALTH PROGRAM; HEALTH PROMOTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERDISCIPLINARY COMMUNICATION; KIDNEY FAILURE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; QUALITATIVE ANALYSIS; RENAL OSTEODYSTROPHY; RISK FACTOR; SCREENING TEST; SMOKING;

EID: 38649089470     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.9-d.6     Document Type: Article

References (22)

1. National Kidney Foundation. Kidney Early Evaluation Program. Available at: www.kidney.org/news/keep/KEEPabout.cfm. Accessed August 25, 2007.
2. The United States Renal Data System. The United States Renal Data System Annual Data Report 2006. Available at: www.usrds.org/adr_2006.htm. Accessed August 25, 2007.
3. Bailie GR, Eisele G, Liu L, et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant. 2005;20:1110-15.
4. Manley HJ, Garvin CG, Drayer DK, et al. Medication prescribing patterns in ambulatory hemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004;19:1842-48.
5. National Kidney Foundation. KDOQI. Am J Kidney Dis. 2006;47(suppl 3):S1-S145.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
7. Sarnak MJ, Levey AS. Epidemiology of cardiac disease in dialysis patients. Semin Dial. 1999;12:69-76.
8. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-61.
9. National Heart, Lung, and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Available at: www.nhlbi.nih.gov/guidelines/hypertension/. Accessed September 13, 2007.
10. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
11. Gaede P, Vedel P, Larsen N, Jensen GV Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.
12. Keane WF, Brenner BM, de Zeeuw D, et al.; RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499-507.
13. Erslev AJ. Erythropoietin. N Engl J Med. 1991;324:1339-44.
14. National Kidney Foundation. National Kidney Foundation releases preliminary anemia guideline update. April 12, 2007. Available at: www.kidney.org/news/newsroom/newsitem.cfm?id=380. Accessed November 20, 2007.
15. Kapur A, Malik IS, Bagger JP, et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am Heart J. 2005;149:13-19.
16. Singh AK, Szczech L, Tang KL, et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-98.
17. Drueke TB, Locatelli F, Clyne N, et al.; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-84.
18. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-90.
19. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530.
20. Ejerblad E, Fored CM, Lindblad P, et al. Association between smoking and chronic renal failure in a nationwide population-based case-control study. J Am Soc Nephrol. 2004;15:2178-85.
21. Imperatore G, Cadwell BL, Geiss L, et al. Thirty-year trends in cardiovascular risk factor levels among U.S. adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol. 2004;160:531-39.
22. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12:1713-20.